Annual FCF
-$307.51 M
-$16.82 M-5.79%
December 31, 2022
Summary
- As of February 21, 2025, SRNE annual free cash flow is -$307.51 million, with the most recent change of -$16.82 million (-5.79%) on December 31, 2022.
- During the last 3 years, SRNE annual FCF has fallen by -$123.08 million (-66.73%).
- SRNE annual FCF is now -3237089.47% below its all-time high of $9500.00, reached on December 31, 2005.
Performance
SRNE Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
-$55.80 M
-$6.25 M-12.62%
June 30, 2023
Summary
- As of February 21, 2025, SRNE quarterly free cash flow is -$55.80 million, with the most recent change of -$6.25 million (-12.62%) on June 30, 2023.
- Over the past year, SRNE quarterly FCF has dropped by -$6.25 million (-12.62%).
- SRNE quarterly FCF is now -5003.25% below its all-time high of $1.14 million, reached on June 30, 2015.
Performance
SRNE Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM FCF
-$243.21 M
+$27.89 M+10.29%
June 30, 2023
Summary
- As of February 21, 2025, SRNE TTM free cash flow is -$243.21 million, with the most recent change of +$27.89 million (+10.29%) on June 30, 2023.
- Over the past year, SRNE TTM FCF has increased by +$27.89 million (+10.29%).
- SRNE TTM FCF is now -536991.83% below its all-time high of $45.30 thousand, reached on June 30, 2009.
Performance
SRNE TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
SRNE Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -5.8% | -12.6% | +10.3% |
| 3 y3 years | -66.7% | -12.6% | +10.3% |
| 5 y5 years | -179.2% | -12.6% | +10.3% |
SRNE Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -5.8% | at low | -12.6% | +35.1% | at high | +25.9% |
| 5 y | 5-year | -85.2% | at low | -162.8% | +35.1% | -49.4% | +25.9% |
| alltime | all time | <-9999.0% | at low | -5003.3% | +35.1% | <-9999.0% | +25.9% |
Sorrento Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2023 | - | -$55.80 M(+12.6%) | -$243.21 M(-10.3%) |
| Mar 2023 | - | -$49.55 M(-32.0%) | -$271.11 M(-11.8%) |
| Dec 2022 | -$307.51 M(+5.8%) | -$72.86 M(+12.1%) | -$307.51 M(-0.5%) |
| Sep 2022 | - | -$65.01 M(-22.3%) | -$309.00 M(-5.9%) |
| Jun 2022 | - | -$83.69 M(-2.6%) | -$328.28 M(+0.5%) |
| Mar 2022 | - | -$85.95 M(+15.6%) | -$326.59 M(+12.4%) |
| Dec 2021 | -$290.69 M(+75.0%) | -$74.35 M(-11.8%) | -$290.69 M(+22.4%) |
| Sep 2021 | - | -$84.29 M(+2.8%) | -$237.58 M(+7.5%) |
| Jun 2021 | - | -$82.01 M(+63.8%) | -$221.08 M(+24.5%) |
| Mar 2021 | - | -$50.05 M(+135.7%) | -$177.54 M(+6.9%) |
| Dec 2020 | -$166.06 M(-10.0%) | -$21.23 M(-68.7%) | -$166.06 M(-9.1%) |
| Sep 2020 | - | -$67.79 M(+76.2%) | -$182.71 M(+12.2%) |
| Jun 2020 | - | -$38.47 M(-0.3%) | -$162.85 M(-6.1%) |
| Mar 2020 | - | -$38.57 M(+1.8%) | -$173.47 M(-5.9%) |
| Dec 2019 | -$184.44 M(+50.0%) | -$37.88 M(-21.0%) | -$184.44 M(-6.4%) |
| Sep 2019 | - | -$47.92 M(-2.4%) | -$196.98 M(+14.1%) |
| Jun 2019 | - | -$49.09 M(-0.9%) | -$172.70 M(+16.6%) |
| Mar 2019 | - | -$49.54 M(-1.8%) | -$148.09 M(+20.4%) |
| Dec 2018 | -$122.96 M(+11.6%) | -$50.42 M(+113.3%) | -$122.96 M(+3.3%) |
| Sep 2018 | - | -$23.64 M(-3.5%) | -$118.99 M(+7.6%) |
| Jun 2018 | - | -$24.49 M(+0.3%) | -$110.60 M(+1.9%) |
| Mar 2018 | - | -$24.41 M(-47.5%) | -$108.49 M(-1.5%) |
| Dec 2017 | -$110.15 M(+41.6%) | -$46.45 M(+204.6%) | -$110.15 M(+32.1%) |
| Sep 2017 | - | -$15.25 M(-31.8%) | -$83.39 M(-9.0%) |
| Jun 2017 | - | -$22.37 M(-14.2%) | -$91.64 M(+10.3%) |
| Mar 2017 | - | -$26.07 M(+32.4%) | -$83.08 M(+6.8%) |
| Dec 2016 | -$77.79 M(+69.9%) | -$19.69 M(-16.2%) | -$77.79 M(+2.3%) |
| Sep 2016 | - | -$23.51 M(+70.2%) | -$76.02 M(+5.1%) |
| Jun 2016 | - | -$13.81 M(-33.5%) | -$72.32 M(+26.1%) |
| Mar 2016 | - | -$20.78 M(+16.0%) | -$57.37 M(+25.3%) |
| Dec 2015 | -$45.78 M(+55.9%) | -$17.92 M(-9.5%) | -$45.78 M(+28.3%) |
| Sep 2015 | - | -$19.80 M(-1840.3%) | -$35.67 M(+64.4%) |
| Jun 2015 | - | $1.14 M(-112.4%) | -$21.70 M(-26.0%) |
| Mar 2015 | - | -$9.19 M(+17.6%) | -$29.33 M(-0.1%) |
| Dec 2014 | -$29.36 M(+68.5%) | -$7.81 M(+34.0%) | -$29.36 M(+1.9%) |
| Sep 2014 | - | -$5.83 M(-10.2%) | -$28.81 M(+8.3%) |
| Jun 2014 | - | -$6.49 M(-29.6%) | -$26.61 M(+11.1%) |
| Mar 2014 | - | -$9.22 M(+26.8%) | -$23.95 M(+37.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2013 | -$17.42 M(+300.9%) | -$7.27 M(+100.7%) | -$17.42 M(+51.0%) |
| Sep 2013 | - | -$3.62 M(-5.6%) | -$11.53 M(+26.9%) |
| Jun 2013 | - | -$3.84 M(+42.7%) | -$9.09 M(+51.2%) |
| Mar 2013 | - | -$2.69 M(+94.1%) | -$6.01 M(+38.3%) |
| Dec 2012 | -$4.34 M(+14.5%) | -$1.39 M(+17.5%) | -$4.34 M(+16.2%) |
| Sep 2012 | - | -$1.18 M(+56.0%) | -$3.74 M(+16.4%) |
| Jun 2012 | - | -$756.40 K(-26.1%) | -$3.21 M(-24.5%) |
| Mar 2012 | - | -$1.02 M(+31.1%) | -$4.25 M(+12.1%) |
| Dec 2011 | -$3.80 M(+138.3%) | -$780.10 K(+19.7%) | -$3.79 M(+20.7%) |
| Sep 2011 | - | -$651.90 K(-63.8%) | -$3.14 M(+16.3%) |
| Jun 2011 | - | -$1.80 M(+219.3%) | -$2.70 M(+92.0%) |
| Mar 2011 | - | -$563.50 K(+338.2%) | -$1.41 M(-11.6%) |
| Dec 2010 | -$1.59 M(+104.1%) | -$128.60 K(-39.5%) | -$1.59 M(-20.0%) |
| Sep 2010 | - | -$212.40 K(-57.8%) | -$1.99 M(-3.2%) |
| Jun 2010 | - | -$503.80 K(-32.6%) | -$2.06 M(+35.9%) |
| Mar 2010 | - | -$748.00 K(+42.1%) | -$1.51 M(+93.8%) |
| Dec 2009 | -$780.50 K(<-9900.0%) | -$526.50 K(+89.9%) | -$780.40 K(+805.3%) |
| Sep 2009 | - | -$277.30 K(-805.6%) | -$86.20 K(-290.3%) |
| Jun 2009 | - | $39.30 K(-347.2%) | $45.30 K(-508.1%) |
| Mar 2009 | - | -$15.90 K(-109.5%) | -$11.10 K(<-9900.0%) |
| Dec 2008 | $0.00(-100.0%) | $167.70 K(-215.0%) | $100.00(-100.1%) |
| Sep 2008 | - | -$145.80 K(+752.6%) | -$175.70 K(+312.4%) |
| Jun 2008 | - | -$17.10 K(+263.8%) | -$42.60 K(-26.8%) |
| Mar 2008 | - | -$4700.00(-42.0%) | -$58.20 K(-91.3%) |
| Dec 2007 | -$668.10 K(<-9900.0%) | -$8100.00(-36.2%) | -$668.00 K(+1.2%) |
| Sep 2007 | - | -$12.70 K(-61.2%) | -$659.90 K(+2.0%) |
| Jun 2007 | - | -$32.70 K(-94.7%) | -$647.20 K(+5.3%) |
| Mar 2007 | - | -$614.50 K(-6568.4%) | -$614.50 K(-6568.4%) |
| Dec 2006 | $0.00(-100.0%) | - | - |
| Dec 2005 | $9500.00(>+9900.0%) | $9500.00(>+9900.0%) | $9500.00(>+9900.0%) |
| Sep 2005 | - | $0.00(0.0%) | $0.00(0.0%) |
| Jun 2005 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2005 | - | $0.00(0.0%) | $0.00(0.0%) |
| Dec 2004 | $0.00(0.0%) | $0.00(0.0%) | $0.00(0.0%) |
| Sep 2004 | - | $0.00(0.0%) | $0.00(0.0%) |
| Jun 2004 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2004 | - | $0.00 | $0.00 |
| Dec 2003 | $0.00 | - | - |
FAQ
- What is Sorrento Therapeutics annual free cash flow?
- What is the all time high annual FCF for Sorrento Therapeutics?
- What is Sorrento Therapeutics annual FCF year-on-year change?
- What is Sorrento Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Sorrento Therapeutics?
- What is Sorrento Therapeutics quarterly FCF year-on-year change?
- What is Sorrento Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Sorrento Therapeutics?
- What is Sorrento Therapeutics TTM FCF year-on-year change?
What is Sorrento Therapeutics annual free cash flow?
The current annual FCF of SRNE is -$307.51 M
What is the all time high annual FCF for Sorrento Therapeutics?
Sorrento Therapeutics all-time high annual free cash flow is $9500.00
What is Sorrento Therapeutics annual FCF year-on-year change?
Over the past year, SRNE annual free cash flow has changed by -$16.82 M (-5.79%)
What is Sorrento Therapeutics quarterly free cash flow?
The current quarterly FCF of SRNE is -$55.80 M
What is the all time high quarterly FCF for Sorrento Therapeutics?
Sorrento Therapeutics all-time high quarterly free cash flow is $1.14 M
What is Sorrento Therapeutics quarterly FCF year-on-year change?
Over the past year, SRNE quarterly free cash flow has changed by -$6.25 M (-12.62%)
What is Sorrento Therapeutics TTM free cash flow?
The current TTM FCF of SRNE is -$243.21 M
What is the all time high TTM FCF for Sorrento Therapeutics?
Sorrento Therapeutics all-time high TTM free cash flow is $45.30 K
What is Sorrento Therapeutics TTM FCF year-on-year change?
Over the past year, SRNE TTM free cash flow has changed by +$27.89 M (+10.29%)